Clinical trial: NCT00583024
Section: Alternatives
Subsections: What Other Treatment Options Are There?

5  
  
Before you decide whether or not to be in this study, your study physician will discuss other options that are available to you. Instead of being in this study, alternatives which could be considered in your case may include hormonal therapy if you are not already on this treatment. Taxanes have also shown to have limited benefit for some patients. Your study physician can provide detailed information about your disease and the benefits of alternative therapies. You should feel free to discuss your case and prognosis with your health care provider.
Clinical trial: NCT00583024
Section: Confidentiality
Subsections: What About Confidentiality?|Will My Health Information Be Used During This Study?

We will keep your participation in this research study confidential to the extent permitted by law. However, it is possible that other people may become aware of your participation in this study. For example, federal government regulatory agencies, the National Institutes of Health/Office of Biologic Activities (NIH/OBA),
the Department of Defense, the U.S. Food and Drug Administration, auditing departments from the University of Iowa, and the University of Iowa Institutional Review Board (a committee that reviews and approves research studies) may inspect and copy records pertaining to this research. Some of these records could contain information that personally identifies you.  
In the future, the granting agency may continue to use your health information that is collected as part of this study. For example, they may combine information from this study with the results of other studies to re-analyze the safety and effectiveness of the study medication, to evaluate other products or therapies, to develop a better understanding of a disease, or to improve the design of future research studies. The funding agency may also share information from this study with regulatory agencies in foreign countries.  
To help protect your confidentiality, we will assign a specific coded number to your file that will appear on the data forms and files, all written files will be kept in a locked office and information on computers will be protected by secure passwords. Only your University of Iowa Hospitals and Clinics or VA Medical Center records will contain information that associates your name with the research study. If we write a report or article about this study or share the study data set with others, we will do so in such a way that you cannot be directly identified. The University of Iowa Hospitals and Clinics generally requires that we document in your medical record chart that you are participating in this study. The information included in the chart will provide contact information for the research team as well as information about the risks associated with this study. We will keep this Informed Consent Document in our research files; it will not be placed in your medical record chart.

The Federal Health Insurance Portability and Accountability Act (HIPAA) requires the University of Iowa Health Care or Iowa City VA Medical Center to obtain your permission for the research team to access or create "protected health information" about you for purposes of this research study. Protected health information is information that personally identifies you and relates to your past, present, or future physical or mental health condition or care. We will access or create health information about you, as described in this document, for purposes of this research study and for your treatment. Once the University of Iowa Health Care or Iowa City VA Medical Center has disclosed your protected health information to us, it may no longer be protected by the Federal HIPAA privacy regulations, but we will continue to protect your confidentiality as described under "Confidentiality." We may share your health information related to this study with other parties including federal government regulatory agencies, the University of Iowa Institutional Review Boards and support staff, You cannot participate in this study unless you permit us to use your protected health information. If you choose not to allow us to use your protected health information, we will discuss any non-research alternatives available to you. Your decision will not affect your right to medical care that is not researchrelated. Your signature on this Consent Document authorizes the University of Iowa Health Care to give us permission to use or create health information about you.  
  
Although you may not be allowed to see study information until after this study is over, you may be given access to your health care records by contacting your health care provider. Your permission for us to access or create protected health information about you for purposes of this study has no expiration date.  
You may withdraw your permission for us to use your health information for this research study by sending a written notice to David M. Lubaroff, PhD, Department of Urology, 200 Hawkins Drive, Iowa City, IA
52242. However, we may still use your health information that was collected before withdrawing your permission. Also, if we have sent your health information to a third party, such as the study sponsor, or we have removed your identifying information, it may not be possible to prevent its future use. You will receive a copy of this signed document.
Clinical trial: NCT00583024
Section: Duration of Study Involvement
Subsections: How Long Will I Be In This Study?

If you agree to take part in this study, your involvement will last for approximately 2 years, perhaps longer. Much depends upon the effect of the vaccine on your cancer. You will receive a total of three vaccinations. After each of the vaccinations, you will be asked to stay in our Clinical Research Unit (CRU)
for 2 hours so we can monitor how you respond to the vaccination. You will be asked to return to the clinic at regularly scheduled times after the vaccination to undergo a physical examination and blood tests to evaluate whether the vaccine is causing any side effects. On some visits you will also have xrays and scans to follow the progress of your prostate cancer following the vaccinations. Following the first vaccinations you will have visits on days 30 (vaccination 2), 44, 60 (vaccination 3), 74, 90, and 6, 9, and 12 months. Depending upon how you respond to the vaccination you will be asked to return every six months after the 12 month visit and have the same examinations and blood tests. These visits will continue until you show progression of your prostate cancer. If you are a patient from the Mercy Cancer Center, Des Moines, IA (hereafter referred to as DMMCC) your follow up visits on days 44, 74 and 6, 9, and 12 months plus any subsequent visits will take place at the DMMCC. Immune responses are measured in this study as a measure of the effects of vaccination. However, if your cancer were to grow despite the vaccinations, the study team would still be interested in obtaining additional measurements of your immune response up to the 12 month time point, in order to better understand how the vaccine works. Do you agree to return for additional study visits and research lab tests to document immune response, every 3 months for up to 12 months from study entry, in case your cancer progresses prior to the 12 month time point? (Circle one) YES NO (initials)
Clinical trial: NCT00583024
Section: Possible Risks, Discomforts, and Inconveniences
Subsections: What Are The Risks Of This Study?|Likely/Common Risks (More Than 35%)|What If I Am Injured As A Result Of This Study?

There may be some risks from being in this research study. This study uses a form of gene transfer.  
Since gene transfer is a new method of treating disease not all of the risks associated with this research intervention are known. In a previous study using adenoviruses, a death did occur. In 1999 a young man died from liver failure when a very high dose of an adenovirus was injected directly into the vein leading to the liver. However, results from our first study of the vaccine indicated that none of the subjects suffered any severe vaccine-related side effects when the vaccine was injected subcutaneously.  
However, the first study used a single vaccination whereas this study will use three vaccinations. Preclinical studies in laboratory animals did not produce any adverse events using the three injection schedule to be used in this clinical study. Based upon our first study, the adenovirus vaccine may cause a local redness and swelling at the site of vaccination, some flu or cold like symptoms, a decrease in white blood cell count (which could result in an increased risk of infection), temporary leakage of protein into your urine, headaches, or fever. Temporary leakage of protein into the urine, which in small amounts does not cause any adverse effects. In large amounts, it can cause swelling and kidney damage in the short or long term. However, the chances of large amounts of protein leakage are very small. If you experience discomfort as a result of the vaccinations you may take over the counter pain relief such as aspirin, Tylenol, or ibuprofen. Do not use any oral steroids such as prednisone as this will depress your ability to develop immune responses to the PSA and compromise the research study.  
The vaccine will be mixed with collagen and injected into your thigh. Although there were no additional side effects when the vaccine was administered in collagen as compared to the vaccine alone in the first study, there is the possibility of infection, fluid accumulation or bruising at the injection site. If this occurs you may take the same over the counter medications listed above that will ease your discomfort and lower any fever that may occur, but do not take oral steroids. There may be some local tenderness, reddening, or swelling at the vaccination site, but this will normally disappear within a few days. The PSA vaccine may induce antibodies against PSA protein. This could interfere with the ability of your health care provider to monitor your PSA blood levels. The antibodies to PSA may lower the amount of the PSA protein in your blood that would not necessarily reflect a clinical change in your cancer. For example, the anti-PSA antibodies may attach to the PSA in your blood and that would not permit the PSA to be measured by the current tests. We are working with other scientists to study this possibility. We are not certain how long the potential for lowering your serum PSA levels will last during the study. However, other methods of follow-up include physical examination, imaging studies (for example, CT, MRI, bone scan), and selected laboratory studies such as alkaline phosphatase will still be useful to follow your disease. Results of these tests will be included in a letter to your local referring physician. The Ad/PSA vaccine will be injected in a collagen Gelfoam matrix, a mixture that has been shown in our pre-clinical research to enhance the production of immune responses to the PSA protein. Gelfoam is a product derived from pigs.  
- If you object to the use of, or are allergic to, a pork product you cannot participate in this study.  
Your physician will be checking you closely to see if any side effects are occurring. Routine blood and urine tests will be done to monitor the effects of the investigational vaccine. Many side effects disappear after the drug is stopped. In the meantime, your health care provider may prescribe medications to keep these side effects under control.  

IRB ID \#: 200605710 APPROVAL DATE: 04/15/13 EXPIRATION DATE: 04/15/14 There is no need for the use of contraceptive devices following injection of the adenovirus/PSA vaccine since the virus will not be present in the semen and cannot be transmitted to your partner.  
The following summarizes the known risks of the Ad/PSA vaccine. There is still very limited experience with the vaccine and there could be other side effects we do not yet know about. As with any investigational product, there is always some chance of unexpected serious or even life-threatening side effects.

Life Threatening - none Serious - none Mild - local tenderness, reddening, swelling at vaccination site Less Likely/Less Common (10% - 35%) Life Threatening - none Serious - none Mild - none Rare (less than 10%)
Life Threatening - none Serious - decrease in white blood cell count Mild - flu or cold-like symptoms protein leakage into urine headache fever BLOOD DRAW
During the screening for eligibility and all follow up visits you will have blood drawn for testing. This may cause bruising or infection at the needle site and/or fainting. We will attempt to minimize these possible side effects by using a trained professional for all blood draws. Likely/Common Risks (more than 35%) Life Threatening - none Serious - none Mild - local tenderness, reddening, swelling at blood draw site

- If you are injured or become ill from taking part in this study, medical treatment is available at the University of Iowa Hospitals and Clinics.  
- No compensation for treatment of research-related illness or injury is available from the University of Iowa unless it is proven to be the direct result of negligence by a University employee.  
- If you experience a research-related illness or injury, you and/or your medical or hospital insurance carrier will be responsible for the cost of treatment.  
- If you are hurt or get sick because of this research study, you can also receive medical care at an Army hospital or clinic free of charge. You will only be treated for injuries that are directly caused by the research study. The Army will not pay for your transportation to and from the hospital or clinic. If you have questions about this medical care, talk to the principal investigator for this study, (David M.  
Lubaroff, PhD, 319-335-8423). If you pay out-of-pocket for medical care elsewhere for injuries caused by this research study, contact Dr. Lubaroff. If the issue cannot be resolved, contact the U.S. Army Medical Research and Materiel Command (USAMRMC) Office of the Staff Judge Advocate (legal office) at (301) 619-7663/2221.  
- In the event of an emergency you should seek immediate care by calling 911, your local physician, the University of Iowa (319-356-1616) or Iowa City VA Medical Center urology staff on call (319-3380581).  
  
7
Clinical trial: NCT00583024
Section: Procedures
Subsections: What Will Happen During This Study?

If you are interested in participating in this study, you will first be asked to sign this informed consent document before any research specific testing is initiated. Once the consent has been signed, you will be scheduled to complete tests and procedures to determine if you are eligible to participate in this study. By signing this Informed Consent document you grant permission for the study investigators to access your medical records for the purposes of evaluating your eligibility for entrance into this vaccine study. If you are eligible and wish to participate, you will receive the vaccine once every 30 days for a total of three vaccinations. Listed below are the tests and procedures that take place for screening and at the study visits.  
SCREENING VISIT:
- Physical exam - Chest X-ray
- Abdominal/pelvic CT
- Bone scan
- Blood tests* - Urine tests
VISIT 1 (first vaccination):
- Physical exam
- Blood tests* 2 IRB ID \#: 200605710 APPROVAL DATE: 04/15/13 EXPIRATION DATE: 04/15/14 VISIT 2 (second vaccination):
- Physical exam - Blood tests*
- Urine test
- Chest X-raya VISITS 3 AND 5 (Days 44 and 74 ):
- Blood tests* VISIT 4 (third vaccination):
- Physical exam
- Blood tests* - Urine tests
- Chest X-raya VISIT 6 (Day 90):
- Physical exam
- Blood tests*
- Urine tests
- Chest X-raya
- Bone Scan VISIT 8 (9 months):
- Blood tests*
- Chest X-raya VISITS 7, 9 (6 and 12 months):
- Blood tests*
- Chest x-raya
- Abdominal/pelvic CTb - Bone scan VISITS OCCURING EVERY 6 MONTHS UNTIL COMPLETION OF STUDY
- Blood tests*
- Chest X-raya VISITS OCCURING ANNUALLY UNTIL COMPLETION OF THE STUDY
- Abdominal/pelvic CTb
- Bone scan
* 4 tablespoons of blood will be obtained at each time point for all clinical and research testing of blood counts, liver function, and kidney function.  
a Will be performed only if the results are abnormal at screening or if a fever develops.  
b Will be performed only if the results are abnormal at screening.  
PSA measurements, CT and bone scans would routinely be used to follow your disease and would be considered standard of care. Laboratory measurements such as blood tests are also used to follow the health of a prostate cancer patient, but if you are in this research study, these tests will be done more 3  
  
often than they normally would. Therefore, they would be considered part of the research protocol rather than standard of care.
Clinical trial: NCT00583024
Section: Purpose of Research
Subsections: What Is The Purpose Of This Study?

1
This is a research study. We are inviting you to participate in this research study because you have hormone refractory cancer of the prostate, that is, your prostate cancer is no longer responding to hormone therapy. This study involves a research intervention with an Ad/PSA vaccine. This is a virus vaccine in which the gene for prostate specific antigen (PSA) has been placed into a common cold virus termed adenovirus (Ad) to produce this Ad/PSA product. Adenovirus is a common virus found in human respiratory systems. In its normal state, it can reproduce and cause a respiratory infection. Respiratory illnesses caused by adenovirus infections range from the common cold to pneumonia, croup and bronchitis. The adenovirus used in this research study will not be infectious, but may still cause flu or cold like symptoms. PSA is produced by normal and cancerous prostate cells. Since you may have previously been treated for your prostate cancer by surgery or irradiation the only cells that will be secreting PSA are the remaining cancer cells. The purpose of this study is to determine whether vaccination with the Ad/PSA prostate cancer vaccine will activate your immune system against PSA, which might have a positive effect on prostate cancer.  
Other scientists have also been working on cancer vaccines and, although many show promising results in pre-clinical studies and are in Phase II and Phase III clinical studies, none have been approved for therapeutic use. The Ad/PSA vaccine is considered investigational, which means that it has not been approved by the U.S. Food and Drug Administration.
Clinical trial: NCT00583024
Section: Voluntary Participation
Subsections: Is Being In This Study Voluntary?

Taking part in this research study is completely voluntary. You may choose not to take part at all. If you decide to be in this study, you may stop participating at any time. If you decide not to be in this study, or if you stop participating at any time, you won't be penalized or lose any benefits for which you otherwise qualify.
Clinical trial: NCT00583024
Section: Withdrawal from Study
Subsections: What If I Decide To Drop Out Of The Study?|Can Someone Else End My Participation In This Study?

If you decide to leave the study early, we will ask that you meet with one of the research study team members to provide the reasons for withdrawal. We will, of course, honor your request and there will not be any consequences to your withdrawal.

Under certain circumstances, the researchers or the study sponsor might decide to end your participation in this research study earlier than planned. This might happen for any one or more of the following reasons: (a) in our judgment it would not be safe for you to continue, (b) because your condition has become worse, (c) because funding for the research study has ended, (d) the data and safety monitoring committee has closed the study due to a low number of subjects entered into the study.